Upcoming Meetings
The CSRC, Health and Environmental Sciences Institute (HESI), and the FDA convened a two-day meeting titled, "The Future of the Assessment of Drug-Induced Arrhythmias and the Comprehensive In Vitro Proarrythmia Assay (CiPA)," on May 21-22 in Washington, D.C. Visit the CSRC website to view the agenda and presentations. The meeting synopsis is available here.
CiPA at SPS: Sessions on Tuesday September 26 and Wednesday, September 27, 2017
In Silico Modeling for Cardiac Drug Safety session. Presentation by Dr. Zhihua Li available here.
CiPA Challenges and Opportunities from Nonclinical, Clinical, and Regulatory Perspectives. Learn more on the meeting website here.
Related Meetings & Webinars
BioPharma Research Council Webinar. Focus on the CiPA paradigm: Update from the front lines. Presented by Dr. Bernard Fermini, Pfizer Inc, June 2, 2016.
GE Cell Technologies, Assessment of the potential for drugs to cause cardiac arrhythmias: Evolving response to a problem in drug development: presented by Dr. Norman Stockbridge, US FDA, 11/28/2012
CSPS, Assessment of the potential for drugs to cause cardiac arrhythmias (In Chinese): presented by Dr. Norman Stockbridge, US FDA, 6/5/2013
DIA Webinar, The New Paradigm: Next Steps: presented by Dr. Norman Stockbridge, US FDA, 10/30/2013
Stanford University, Drug Safety Cultural, Scientific, and Engineering Issues: presnted by Dr. Norman Stockbrige, US FDA, 12/2/2013
Pacific Coast Statisticians and Pharmacometricians Innovation Conference, Beyond QT—The Comprehensive in Vitro Proarrhythmia Assay: presented by Dr. Norman Stockbridge, US FDA, 2/26/2014
DIA Annual Meeting, Implementation and Implications of Non-Clinical Proarrhythmia Assessment: presented by Dr. Norman Stockbridge, US FDA, 6/13/2014
DIA 2014 Annual Meeting, The Need for a new paradigm to assess proarrhythmic effects of drugs: presented by Dr. Philip Sager, 6/14/2014
AACP, Proarrhythmic Assessment of Drugs: Need for a new paradigm: presented by Dr. Philip Sager, 7/8/2014
Safety Pharmacology Society, Comprehensive in vitro Proarrhythmia Assay: CIPA: presented by Dr. Norman Stockbridge, US FDA, 9/11/2014
American College of Clinical Pharmacology (ACCP), The Comprehensive* in Vitro Proarrhythmia Assay: presented by Dr. Norman Stockbridge, US FDA, 9/13/2014
Regulatory Affairs Professionals Society (RAPS), Evolution of testing pharmaceuticals for proarrhythmic potential: An example of applied regulatory science: presented by Dr. Norman Stockbridge, US FDA, 9/28/2014
DIA-Japan, Comprehensive in vitro Proarrhythmia Assay: CIPA: presented by Dr. Norman Stockbridge, US FDA, 9/28/2014
DIA Japan, The New Paradigm for Proarrhythmia Assessment without the TQT Study: presented by Dr. Philip Sager, 10/22/2014
American Association of Pharmaceutical Scientists, Current and future assessment of cardiotoxicity beyond the TQT: presented by Dr. Norman Stockbridge, US FDA, 11/3/2014
ACT Annual Meeting, Proarrhythmic Assessment of Drugs: The Need for a New Paradigm: presented by Dr. Philip Sager, 11/8/2014
American College of Toxicology, A regulatory perspective on assessment of cardiotoxicity Beyond QTc: presented by Dr. Norman Stockbridge, US FDA, 11/10/2014
DIA-China, Shifting Gears to Non-Clinical Pro-Arrhythmia Models: Rationale and Scope of the Proposed CiPA Paradigm: presented by Dr. Norman Stockbridge, US FDA, 11/22/2014
CBI Drug Safety Meeting, The In Vitro Evaluation of ProA Risk - The Evolving CIPA Paradigm: presented by Dr. Gary Gintant, AbbVie, 2/9/2015
CSRC Annual Meeting, Current Status, Opportunities and Challenges: presented by Dr. Hugo Vargas, Amgen, 2/18/2015
American Society for Clinical Pharmacology and Therapeutics, Emerging approaches to assess proarrhythmic risk: Regulatory perspective: presented by Dr. Norman Stockbridge, US FDA, 3/6/2015